Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.
Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.
The agreement gives Alimera the exclusive option to license a unique class of compounds, NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidise inhibitors, as a potential treatment for conditions such as dry age-related macular degeneration (AMD).
Alimera will also receive the exclusive rights to sublicense in ophthalmology and the exclusive rights for non-ophthalmic use. The company will be responsible for the development and commercialization of the compounds and Emory will receive milestone payments and royalties from net sales.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.